CHUGAI PHARMACEUTICAL CO., LTD.
- Country
- 🇯🇵Japan
- Ownership
- Public, Subsidiary
- Established
- 1925-03-10
- Employees
- 7.6K
- Market Cap
- $83.6B
The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)
- Conditions
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 470
- Registration Number
- NCT04818983
- Locations
- 🇯🇵
Hyogo Cancer Center, Akashi, Japan
🇯🇵Nippon Medical School Hospital, Bunkyō-Ku, Japan
🇯🇵National Cancer Center Hospital, Chuo Ku, Japan
A Clinical Pharmacology Study to Evaluate the Effect of GYM329 on Disuse Muscle Atrophy in Healthy Volunteer
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 30
- Registration Number
- NCT04708847
- Locations
- 🇳🇱
QPS Netherlands B.V., Groningen, Netherlands
Excretion Balance, PK and Metabolism of a Single Oral Dose of [14C]PCO371
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2021-03-01
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 11
- Registration Number
- NCT04649216
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, UK, United Kingdom
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
- Conditions
- Interventions
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 113
- Registration Number
- NCT04511845
- Locations
- 🇯🇵
Kurume University Hospital, Kurume, Fukuoka, Japan
🇯🇵National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
🇺🇸Arizona Oncology, Tucson, Arizona, United States
Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)
- Conditions
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 1221
- Registration Number
- NCT04501497
- Locations
- 🇯🇵
Akashi Medical Center, Akashi, Japan
🇯🇵National Hospital Organization Asahikawa Medical Center, Asahikawa, Japan
🇯🇵Nippon Medical School Hospital, Bunkyō-Ku, Japan
A Clinical Study Investigating the Safety, Tolerability, PK and PD of PCO371 in Patients With Hypoparathyroidism
- First Posted Date
- 2019-12-24
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 5
- Registration Number
- NCT04209179
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
🇺🇸Indiana University School of Medicine, Indianapolis, Indiana, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2019-10-31
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 112
- Registration Number
- NCT04097444
- Locations
- 🇯🇵
Ac Medical Inc., Chuo Ku, Tokyo, Japan
PD-L1 Expression in Japanese Renal Cell Carcinoma Patients
- Conditions
- First Posted Date
- 2018-11-21
- Last Posted Date
- 2021-08-30
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 830
- Registration Number
- NCT03748901
- Locations
- 🇯🇵
Aichi Medical University, Nagoya-city, Aichi, Japan
A Study of Atezolizumab in Patients With Unresectable, Locally Advanced or Metastatic NSCLC (J-TAIL)
- Conditions
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 1026
- Registration Number
- NCT03645330
- Locations
- 🇯🇵
National Hospital Organization Okinawa National Hospital, Ginowan, Japan
🇯🇵National Hospital Organization Asahikawa Medical Center, Asahikawa, Japan
🇯🇵Asahikawa Medical University Hospital, Asahikawa, Japan
A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis
- First Posted Date
- 2016-11-16
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 26
- Registration Number
- NCT02965053